What is carcinoma ex pleomorphic adenoma?
Carcinoma ex pleomorphic adenoma (CXPA) is a salivary gland cancer that develops inside a benign tumour called a pleomorphic adenoma. “Ex” simply means “arising from”. The benign tumour is usually present for years, sometimes decades, before part of it turns malignant.
Pleomorphic adenoma is the most common salivary gland tumour and is almost always harmless when removed completely. Only a small proportion ever becomes cancerous. The risk rises the longer an adenoma is left in place and is higher after repeated recurrences of an adenoma that was not fully removed.
CXPA makes up roughly one in ten salivary gland cancers. Most cases arise in the parotid gland, in front of the ear, and affect people in their 50s and 60s. A typical story is a lump that has been present for many years and then starts to grow quickly.
The outlook depends strongly on how far the cancer has broken out of the old adenoma and on the type of cancer that has formed inside it. Tumours that stay within the adenoma’s capsule behave almost like benign tumours, while widely invasive ones can be aggressive (Antony et al., 2012).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Malignant salivary gland tumour arising in a pleomorphic adenoma |
| How common | About 3-4% of all salivary tumours; around 1 in 10 salivary cancers |
| Typical age | Adults, mostly 50-70; usually about 10 years older than people with benign adenomas |
| Sex | Men and women affected about equally |
| Main site | Parotid gland (around 8 in 10); also submandibular and minor salivary glands |
| Warning sign | Sudden growth, pain or facial weakness in a long-standing lump |
| Main treatment | Surgery, often followed by radiotherapy |
| Outlook | Varies widely; about 6 in 10 alive at 5 years overall |
2. Types of carcinoma ex pleomorphic adenoma
Pathologists describe CXPA in two ways: how far the cancer has spread beyond the adenoma, and which kind of cancer has developed.
By extent of invasion
| Category | What it means | Usual behaviour |
|---|---|---|
| Intracapsular (non-invasive) | Cancer cells are still entirely inside the adenoma | Excellent; very similar to a benign adenoma |
| Minimally invasive | Cancer has broken through the capsule by only a few millimetres (commonly 4 mm or less) | Usually very good |
| Widely invasive | Cancer has spread well beyond the capsule into surrounding tissue | Higher risk of recurrence and spread |
By the type of cancer inside
| Carcinoma type | Notes |
|---|---|
| Salivary duct carcinoma | The most frequent; high grade and aggressive |
| Adenocarcinoma, not otherwise specified | Common; behaviour depends on grade |
| Myoepithelial carcinoma | Arises from the outer muscle-like cells of glands |
| Epithelial-myoepithelial carcinoma | Usually lower grade |
| Others | Mucoepidermoid, adenoid cystic and other rarer types |
Many tumours are also given a grade. Low-grade carcinomas grow slowly, while high-grade ones such as salivary duct carcinoma tend to spread to lymph nodes.
3. Causes and risk factors
CXPA develops from a pre-existing pleomorphic adenoma. Over time, extra genetic damage builds up in some adenoma cells until they become malignant.
| Risk factor | Notes |
|---|---|
| Long-standing adenoma | The risk grows with the number of years an adenoma has been present |
| Recurrent adenoma | Adenomas that have come back after incomplete removal carry a higher risk |
| Older age | Most people are in their 50s or older |
| Large adenoma | Bigger tumours are more likely to contain cancer |
| Previous radiation | Linked with salivary gland tumours in general |
Gene changes
| Gene change | Notes |
|---|---|
| PLAG1 or HMGA2 rearrangement | Present in the original adenoma; often still found in the carcinoma |
| TP53 changes | Common in high-grade forms |
| HER2 (ERBB2) amplification | Seen in a sizeable share, especially salivary duct type; a treatment target |
| Androgen receptor (AR) | Often present in salivary duct type; a possible treatment target |
| Other changes | PIK3CA, HRAS and others in some tumours (Key et al., 2024) |
These changes arise only in the tumour. CXPA is not inherited.
4. How does it look
On the outside
| Feature | Description |
|---|---|
| Position | Usually in front of or below the ear (parotid); sometimes under the jaw or inside the mouth |
| Shape | A rounded or irregular lump |
| Feel | Firm or hard; may become fixed to the skin or deeper tissues |
| Size | Often 2-6 cm, sometimes much larger after many years |
| Skin | Usually normal; may become red, tethered or ulcerated in advanced cases |
| Change over time | A lump stable for years that suddenly enlarges |
On scans
Ultrasound is often the first test for a lump near the ear. MRI is the best scan for showing the tumour’s edges, any spread into nearby tissue and growth along the facial nerve. Irregular, poorly defined margins and areas of tissue death suggest cancer rather than a simple adenoma. CT of the neck and chest, or a PET-CT, checks lymph nodes and the lungs.
Under the microscope
| Feature | Description |
|---|---|
| Two components | Remnants of the benign adenoma next to clearly malignant tissue |
| Old adenoma | Often scarred, glassy (hyalinised) or calcified |
| Carcinoma | Atypical cells, many cell divisions and areas of necrosis |
| Invasion | Measured in millimetres beyond the capsule |
| Special stains | HER2, androgen receptor and PLAG1 or HMGA2 help with diagnosis and treatment choice |
In some tumours the benign component has almost disappeared, so the diagnosis may rest on the history of a long-standing lump or on finding PLAG1 or HMGA2 changes in the cancer.
5. Symptoms
Common symptoms
- A lump in front of or below the ear, or under the jaw
- A lump that has been there for years and has recently started growing faster
- Pain or discomfort in the lump
- A lump that feels harder or more fixed than before
Less common symptoms
| Symptom | What it may mean |
|---|---|
| Weakness of one side of the face | Facial nerve involvement; an important warning sign |
| Numbness | Nerve involvement |
| Lump in the neck | Lymph node spread |
| Skin ulceration | Advanced local growth |
| Swelling in the mouth or throat | Minor salivary gland tumour |
| Cough or breathlessness | Rarely, spread to the lungs |
When to seek medical advice
Any lump near the ear or under the jaw that persists for more than a few weeks should be checked. If you know you have a pleomorphic adenoma that was not removed, see your doctor promptly if it grows, becomes painful or if your face becomes weak.
6. Diagnosis
| Test | Purpose |
|---|---|
| Examination of the head and neck | Assesses the lump, facial nerve function and lymph nodes |
| Ultrasound | First look at the lump and the neck nodes |
| Fine-needle aspiration or core biopsy | Takes cells or a thin core of tissue; may miss small areas of cancer |
| MRI | Shows extent, edges and nerve involvement |
| CT or PET-CT | Checks the neck, chest and rest of the body for spread |
| Final pathology after surgery | Confirms the diagnosis, invasion distance, carcinoma type and margins |
Needle tests can be misleading, because a small cancer may hide inside a large benign tumour. The diagnosis is therefore often only confirmed after the whole tumour is removed (Antony et al., 2012).
Staging
CXPA is staged in the same way as other major salivary gland cancers, using the TNM system.
| Part | What it describes |
|---|---|
| T (tumour) | Size, and spread beyond the gland into skin, bone, nerves or other structures |
| N (nodes) | Number, size and side of neck lymph nodes containing cancer |
| M (metastasis) | Spread to distant organs such as the lungs or bones |
7. Treatment
Treatment is planned by a head and neck cancer team, which usually includes surgeons, clinical oncologists, pathologists and radiologists.
Surgery
| Operation | Notes |
|---|---|
| Parotidectomy | Removes part or all of the parotid gland with the tumour |
| Facial nerve preservation | The nerve is kept when it is not involved by cancer |
| Facial nerve resection and repair | If the nerve runs through the tumour; a graft may restore some movement |
| Submandibular gland excision | For tumours under the jaw |
| Neck dissection | Removes lymph nodes when they are involved, and often for high-grade or large tumours |
| Wide local excision | For tumours of the minor salivary glands in the mouth or throat |
For intracapsular and minimally invasive tumours removed with clear margins, surgery alone may be enough.
Radiotherapy
Radiotherapy after surgery is commonly advised for widely invasive, high-grade, node-positive or incompletely removed tumours. In a recent two-centre series, about three-quarters of patients received radiotherapy after surgery (Kassalow et al., 2025).
Drug treatment
| Option | When it may be used |
|---|---|
| HER2-targeted drugs | For HER2-positive tumours that have spread or come back |
| Androgen deprivation therapy | For androgen receptor-positive tumours |
| Chemotherapy | Sometimes with radiotherapy, or for advanced disease |
| Clinical trials | Testing targeted drugs and immunotherapy |
Testing the tumour for HER2 and androgen receptor is useful because these results can open up targeted treatment options.
Side effects
| Treatment | Possible side effects |
|---|---|
| Parotid surgery | Temporary or permanent facial weakness; numbness of the ear lobe; a dent in front of the ear |
| Frey syndrome | Sweating or flushing of the cheek when eating |
| Neck dissection | Shoulder stiffness, neck numbness, swelling |
| Radiotherapy | Skin soreness, dry mouth, taste changes, hearing changes, jaw stiffness |
What treatment involves day to day
| Stage | What to expect |
|---|---|
| Surgery | Usually 1-3 nights in hospital, with a drain for a day or two |
| Recovery | Most people return to normal activities within 2-4 weeks |
| Radiotherapy | Weekday treatments for around 6 weeks, starting 4-8 weeks after surgery |
| Facial weakness | Eye care and facial physiotherapy if needed |
8. Outlook (prognosis)
A systematic review of almost 5,600 patients found overall survival of about 72% at 3 years, 62% at 5 years and 45% at 10 years. Higher stage, lymph node spread, high grade and invasion beyond 1.5 mm were linked with poorer survival (Key et al., 2022).
| Factor | Effect on outlook |
|---|---|
| Intracapsular or minimally invasive | Excellent, close to that of a benign adenoma |
| Widely invasive | Higher risk of recurrence and spread |
| High grade or salivary duct type | Poorer outlook |
| Lymph node spread | One of the strongest predictors of poorer survival (Kassalow et al., 2025) |
| Clear margins | Better local control |
Cancer can return in the original area, in the neck or in distant organs such as the lungs and bones. Most recurrences appear within the first 5 years.
9. Follow-up
| Follow-up | Purpose |
|---|---|
| Clinic visits every 2-3 months at first | Examine the face, scar and neck |
| Gradually longer intervals | Every 6-12 months after the first few years |
| MRI of the head and neck | Looks for local recurrence |
| CT of the chest | Checks the lungs, especially for high-grade tumours |
| Facial nerve, dental and swallowing review | Supports recovery after treatment |
10. Living with carcinoma ex pleomorphic adenoma
- Protect your eye with drops, gel and taping at night if your eyelid does not close fully
- Do facial exercises taught by a physiotherapist if your face is weak
- Look after your teeth, especially after radiotherapy, with regular dental check-ups
- Use saliva substitutes and sip water for a dry mouth
- Report new lumps, pain or numbness without waiting for your next appointment
- Seek support from head and neck cancer charities and patient groups
11. Frequently asked questions
| Question | Answer |
|---|---|
| Can a benign parotid lump really become cancer? | Yes, rarely; this is why pleomorphic adenomas are usually removed |
| Is it inherited? | No |
| Will I lose movement in my face? | Not usually if the nerve is free of tumour, though temporary weakness is common |
| Do I need radiotherapy? | It depends on invasion, grade, margins and lymph nodes |
| Is chemotherapy usually needed? | Not after surgery for most people; it is used mainly for advanced disease |
| Can it come back? | Yes, which is why regular follow-up is important |
| Why test for HER2? | A HER2-positive tumour may respond to targeted drugs |
12. Questions to ask your care team
- How far had the cancer spread beyond the adenoma?
- What type and grade of carcinoma is it?
- Were the margins clear, and was the facial nerve involved?
- Do I need a neck dissection or radiotherapy?
- Has my tumour been tested for HER2 and androgen receptor?
- What follow-up scans will I have?
Resources
- Antony, J. et al. (2012) ‘Carcinoma ex pleomorphic adenoma: a comprehensive review of clinical, pathological and molecular data’, Head and Neck Pathology, 6(1), pp. 1-9.
- Kassalow, B. et al. (2025) ‘Carcinoma ex pleomorphic adenoma: multi-institutional retrospective cohort study’, OTO Open, 9(3), e70147.
- Key, S. et al. (2022) ‘Systematic review of prognostic factors in carcinoma ex pleomorphic adenoma’, Oral Oncology, 133, 106052.
- Key, S. et al. (2024) ‘Molecular factors in carcinoma ex pleomorphic adenoma: systematic review and meta-analysis’, The Laryngoscope, 134(3), pp. 1042-1053.
- National Cancer Institute (2026) Salivary Gland Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/head-and-neck/hp/adult/salivary-gland-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.